Loading your page…
Frontiers in pediatrics
By Chen H, Ali M, Huang H and 3 others.
Intravenous polymyxins remain salvage agents for resistant Gram-negative infections in children, but pediatric evidence on clinical outcomes and toxicity is fragmented.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
We systematically searched PubMed, Embase, Web of Science, the Cochrane Library, CNKI, Wanfang Data, SinoMed, and VIP from inception to 31 January 2025. Eligible studies reported intravenous polymyxin-containing therapy in hospitalized pediatric patients with documented or suspected resistant Gram-negative infections. Random-effects single-arm meta-analyses were used to estimate pooled outcome proportions.
Twenty-four studies comprising 1,152 reported patients or treatment units were included, most of which were single-arm observational studies. The pooled proportions were 22% [95% confidence interval (CI) 16%-27%] for all-cause mortality, 14% (95% CI 11%-17%) for infection-related mortality, 65% (95% CI 58%-72%) for clinical improvement, 13% (95% CI 9%-17%) for overall adverse events, and 10% (95% CI 7%-14%) for nephrotoxicity. Neurotoxicity and hepatotoxicity were infrequently reported. Clinical setting, dosing, outcome definitions, and units of analysis were heterogeneous.
The available evidence describes outcomes observed during intravenous polymyxin-containing therapy in hospitalized children but does not establish comparative efficacy or causality for adverse events. Prospective multicenter pediatric studies using standardized dosing, outcome, and safety definitions are needed.
Published in Frontiers in pediatrics. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
